Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000
Debt
Debt-to-Equity RatioN/A
Current Ratio14.74
Quick Ratio13.13
Price-To-Earnings
Trailing P/E Ratio17.37
Forward P/E Ratio31.02
P/E Growth3.16
Sales & Book Value
Annual Sales$113.42 million
Price / Sales4.43
Cash Flow$2.2596 per share
Price / Cash15.10
Book Value$17.97 per share
Price / Book1.90
Profitability
EPS (Most Recent Fiscal Year)$1.96
Net Income$31.81 million
Net Margins17.64%
Return on Equity10.05%
Return on Assets9.32%
Miscellaneous
Employees123
Outstanding Shares14,740,000
Market Cap$513.28
Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc (NASDAQ:ANIK) released its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.25 by $0.71. The biotechnology company had revenue of $21.30 million for the quarter, compared to analysts' expectations of $24.34 million. Anika Therapeutics had a net margin of 17.64% and a return on equity of 10.05%. The business's quarterly revenue was down 9.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.37 EPS. View Anika Therapeutics' Earnings History.
When is Anika Therapeutics' next earnings date?
What price target have analysts set for ANIK?
3 Wall Street analysts have issued 12-month price targets for Anika Therapeutics' stock. Their predictions range from $34.00 to $39.00. On average, they expect Anika Therapeutics' share price to reach $36.50 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Ratings for Anika Therapeutics.
What is the consensus analysts' recommendation for Anika Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Anika Therapeutics stock?
Here are some recent quotes from research analysts about Anika Therapeutics stock:
- 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (7/4/2018)
- 2. Barrington Research analysts commented, "We expect gross margin to bounce back by a few hundred basis points as the year progresses." (5/4/2018)
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), Intersect ENT (XENT), AtriCure (ATRC), OraSure Technologies (OSUR), Tactile Systems Technology (TCMD) and Cerus (CERS).
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Mr. Joseph G. Darling, CEO, Pres & Director (Age 60)
- Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 43)
- Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 46)
- Mr. Richard Hague, Chief Commercial Officer (Age 58)
- Mr. Charles Sherwood III, VP & Corp. Legal Counsel
Has Anika Therapeutics been receiving favorable news coverage?
News articles about ANIK stock have trended somewhat positive on Friday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anika Therapeutics earned a news impact score of 0.11 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 49.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Anika Therapeutics' major shareholders?
Anika Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.62%) and Municipal Employees Retirement System of Michigan (0.03%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.
Which major investors are selling Anika Therapeutics stock?
ANIK stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Anika Therapeutics company stock in the last year include Charles H Sherwood and Richard Hague. View Insider Buying and Selling for Anika Therapeutics.
How do I buy shares of Anika Therapeutics?
Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of ANIK stock can currently be purchased for approximately $34.12.
How big of a company is Anika Therapeutics?
Anika Therapeutics has a market capitalization of $513.28 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.
How can I contact Anika Therapeutics?
Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
